- Magenta Therapeutics (NASDAQ:MGTA) and bluebird bio (NASDAQ:BLUE) have entered into clinical trial collaboration to evaluate MGTA-145, a CXCR2 agonist, in combination with plerixafor, a CXCR4 antagonist, for mobilization and collection of stem cells in patients with sickle cell disease.
- Under the collaboration, Magenta will undertake preclinical studies and both the companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.
- Recently completed Phase 1 study in healthy volunteers, showed that MGTA-145, in combination with plerixafor can rapidly and reliably mobilize high numbers of functional stem cells in a single day, without the need for granulocyte-colony stimulating factor, a commonly used mobilization agent.
- https://seekingalpha.com/news/3641688-magenta-therapeutics-bluebird-bio-team-up-for-mgtaminus-145-combo-trial-in-sickle-cell
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.